Multi-omics investigation of prospective therapeutic targets for type 1 diabetes.

BACKGROUND

In recent years, the incidence of type 1 diabetes has been rising steadily, positioning its prevention and treatment as a central focus of global public health initiatives. Previous Mendelian randomization (MR) studies have investigated the relationship between proteomics and type 1 diabetes. Consequently, this study aims to identify prospective therapeutic targets for type 1 diabetes through a comprehensive multi-omics analysis.

METHODS

This study primarily utilized the MR method, drawing on genetic data from several large-scale, publicly accessible genome-wide association studies. Within this framework, we applied two-sample MR to evaluate the relationship between five omics components and type 1 diabetes. Finally, we conducted various sensitivity analyses and bidirectional MR to ensure the robustness and reliability of our findings.

RESULTS

The inverse variance weighted method revealed that, following false discovery rate correction, 39 plasma proteins and 3 plasma protein ratios exhibited significant associations with type 1 diabetes. The genetically predicted risk of type 1 diabetes ranged from 0.05 for RBP2 to 394.51 for FMNL1. Furthermore, 4-chlorobenzoic acid levels demonstrated a potential association with type 1 diabetes.

CONCLUSION

Our research identified numerous omics components associated with type 1 diabetes. These findings offer novel insights into the disease's etiology, diagnosis, and treatment.